The randomized, double-blind, placebo-controlled clinical trial was published inEvidence-Based Complementary and Alternative Medicine. The 8-week trial included 90 participants, who were randomized to one of three groups. One group received a placebo; one group received 250mg TamaFlex; and one group received 300mg of TamaFlex Plus, a combination of TamaFlex and an extract of mangosteen fruit rind. All participants had mild-to-moderate osteoarthritis.
The findings: Both treatment groups showed significant improvement in function scores, inflammatory status, and collagen breakdown product in urine samples, as compared to the placebo group. “Moreover,” the researchers wrote, “it is worth noting that the subjects supplemented with the herbal ingredients experienced significant relief from knee pain and showed improved musculoskeletal function starting from day five through the end of the trial. Furthermore, the subgroup analyses on knee pain and functional measures suggested that both interventions yielded significant benefits in the mild (KL-II) and moderate (KL-III) grades OA subjects, starting from day five through the end of the study.”
Related: The Natural View: Innovations in Joint Support 10 Top Healthy Aging Priorities BGG World Announces Astaxanthin Medical Research List Containing 1,200 Studies
Eric Anderson, Managing Director, NXT USA, commented in a press release: “We are thrilled to continue to build the body of evidence confirming the safe and efficacious benefits of TamaFlex, this time in a population desperately in need of relief. Our ingredient fills an unmet need in the joint health market that products like glucosamine and chondroitin just can’t address, namely consumer demands like clean label, vegan, non-GMO, and sustainably sourced. TamaFlex is available in a small daily dose that is fast-acting, long-lasting, and protective. It is the perfect fit for joint health brands looking for an innovative approach to the contemporary joint health consumer.”
